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Heat shock protein 90 inhibition 
abrogates TLR4-mediated 
NF-κB activity and reduces renal 
ischemia-reperfusion injury
Stephen O’Neill1, Duncan Humphries1, George Tse1, Lorna P Marson1, Kevin Dhaliwal1, 
Jeremy Hughes1, James A Ross2, Stephen J Wigmore1 & Ewen M Harrison1
Renal ischemia-reperfusion injury (IRI) is a common cause of acute kidney injury. Toll-like receptor 4 
(TLR4) mediates sterile inflammation following renal IRI. Heat shock protein 90 (Hsp90) inhibition is a 
potential strategy to reduce IRI, and AT13387 is a novel Hsp90 inhibitor with low toxicity. This study 
assessed if pre-treatment with AT13387 could reduce renal IRI and established if the mechanism of 
protection involved a reduction in inflammatory signalling. Mice were pre-treated with AT13387 prior 
to renal IRI. 24 h later, renal function was determined by serum creatinine, kidney damage by tubular 
necrosis score, renal TLR4 expression by PCR and inflammation by cytokine array. In vitro, human 
embryonic kidney cells were co-transfected to express TLR4 and a secreted alkaline phosphatase 
NF-κB reporter. Cells were pre-treated with AT13387 and exposed to endotoxin-free hyaluronan 
to stimulate sterile TLR4-specific NF-κB inflammatory activation. Following renal IRI, AT13387 
significantly reduced serum creatinine, tubular necrosis, TLR4 expression and NF-κB-dependent 
chemokines. In vitro, AT13387-treatment resulted in breakdown of IκB kinase, which abolished TLR4-
mediated NF-κB activation by hyaluronan. AT13387 is a new agent with translational potential that 
reduces renal IRI. The mechanism of protection may involve breakdown of IκB kinase and repression 
of TLR4-mediated NF-κB inflammatory activity.
The rising incidence of acute kidney injury represents a significant global health concern1. Renal 
ischemia-reperfusion injury (IRI) is a common cause of acute kidney injury following blood loss, trauma 
and surgery2. Preventative treatments are currently lacking and apart from supportive renal replacement 
therapy, no other therapies exist for patients who develop acute ischemic kidney injury. The best treat-
ments presently available are avoidance of further kidney damage through careful resuscitation, effective 
treatment of sepsis and avoidance of nephrotoxic medications3.
It has previously been demonstrated that functional and morphological protection from renal IRI in mice 
follows pre-treatment with the Heat shock protein (Hsp) 90 inhibitor 17-dimethylamino-ethylamino-17
-demethoxygeldanamycin (17-DMAG)4. However, the molecular mechanisms of protection from renal 
IRI offered by Hsp90 inhibitors remain to be fully delineated. Defining these mechanisms are essential 
for the further development of these agents and translation to patients.
It is now recognised that inflammation is perhaps the most critical pathophysiological process involved 
in the propagation of renal IRI2. Toll-like receptor 4 (TLR4) is a key regulator of the pro-inflammatory 
transcription factor NF-κ B and plays a dominant role in mediating sterile kidney damage following 
renal IRI5. Iκ B kinase (IKK) activation leads to the dissociation of NF-κ B from Iκ B and its subsequent 
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activation6. Hsp90 may be needed to stabilise the IKK7. Consequently, Hsp90 inhibitors could cause dis-
sociation of the IKK complex, prevention of NF-κ B activation and a reduction in inflammation.
This study investigates the mechanism of protection offered by Hsp90 inhibitors in renal IRI. 
Specifically, it addresses the hypothesis that Hsp90 inhibition represses TLR4-mediated NF-κ B inflam-
matory activity through breakdown of IKK. AT13387 (Astex Pharmaceuticals) is a new small molecule 
Hsp90 inhibitor with a low toxicity profile and better translational potential than 17-DMAG. Therefore 
this study also aims to determine the efficacy of AT13387 in reducing renal IRI8.
Methods
In vivo experiments. Animals. Male FVB/n mice aged 6–8 weeks and weighing 20–25 g, were used 
from in-house colonies. Mice were allowed free access to standard chow and water. The mice were kept 
in a 12:12-h light-dark cycle. All work involving animals was conducted in accordance with the provi-
sions of the UK Animals (Scientific Procedures) Act 1986. The United Kingdom Home Office approved 
all experimental protocols. Procedures were performed under Home Office project license 60/3737 and 
personal license 60/3999.
Drugs. The Hsp90 inhibitor AT13387 was kindly provided by Astex Pharmaceuticals9. For in vivo exper-
iments AT13387 (80 mg/kg free-base equivalent) was dissolved in (2-Hydroxypropyl)-β -cyclodextrin 
(2Hβ C) (Sigma-Aldridge, Dorset, UK), which was prepared in distilled water at 17.5% weight per vol-
ume. Mice were treated by intra-peritoneal injection 24 h prior to surgery. A 2Hβ C vehicle-treated group 
of mice served as the controls.
Renal IRI model. An established model of warm IRI of the left kidney together with a right nephrec-
tomy was used10. The model was designed to inflict a moderate to severe acute tubular injury with 
zero animal mortality. Mice were anesthetised with an intra-peritoneal injection of Ketamine (75 mg/kg, 
Vetalar; Pfizer, Kent, UK) and Medetomidine (1 mg/kg, Domitor, Pfizer). A heated mat maintained body 
temperature with homeostatic control via a rectal temperature probe (Harvard Apparatus, Boston, MA). 
A mid-line laparotomy was performed for access to both kidneys through a single incision. The right 
ureter and renal pedicle were ligated then divided. The right kidney was then removed as a control 
and placed in Methacarn (70% methanol, 20% chloroform, 10% acetic acid). The pedicle of the left 
kidney was dissected and occluded using an atraumatic vascular clamp (Micro Serrefine, Fine Science 
Tools, Linton, UK) for 20 minutes. Following removal of the left pedicle clamp, reperfusion was con-
firmed visually before closure of the abdomen. The anaesthetic was reversed with Atipamezole (1 mg/kg, 
Antisedan, Pfizer), and a subcutaneous injection of 0.9% saline (25 ml/kg) and Buprenorphine (0.1 mg/kg) 
was administered. Animals were recovered in an incubator at 29 °C until tissue collection 24 h later.
Tissue collection. Under terminal general anaesthesia, blood was recovered by intra-cardiac puncture, 
and the serum was stored at − 20 °C. Kidneys were placed immediately into Methacarn, RNAlater (Life 
Technologies, Paisley, UK) or were snap frozen.
Scoring of morphological kidney injury. Hematoxylin and eosin-stained sections were evaluated for tub-
ulointerstitial injury. A series of non-overlapping fields (x200) were examined by an observer blinded to 
the sample number. A scoring system based on the proportion of tubules with necrotic/detached cells 
was used (tubular necrosis score: 0, none; 1, < 30%; 2, 30 –70%; 3, > 70%)4.
Serum creatinine determination. Plasma samples were prepared from whole blood. Creatinine was 
determined using the creatininase/creatinase specific enzymatic method, utilising a commercial kit 
(Alpha Laboratories Ltd, Eastleigh, UK) adapted for use on a Cobas Fara centrifugal analyser (Roche 
Diagnostics Ltd, Welwyn Garden City, UK)11.
Cytokine array panel. Kidney protein lysates (200 μ g per sample) were mixed with biotinylated detec-
tion antibodies. The sample/antibody mixture was then incubated with a mouse cytokine array panel 
(R&D Systems, Abingdon, UK). The panel consisted of a nitrocellulose membrane with capture antibod-
ies for 40 murine cytokines spotted on its surface in a duplicate manner. Cognate immobilized capture 
antibodies on the membrane bound any cytokine/detection antibody complexes present. Following a 
wash to remove unbound material, Streptavidin-HRP and chemiluminescent detection reagents were 
added sequentially followed by development using autoradiography. Light produced at each spot was 
used to determine the amount of cytokine bound. Mean gray values were quantified using Image J 
(National Institutes of Health, USA)12.
Real-time reverse transcriptase–PCR. For the detection of renal TLR4 expression, RNA was extracted 
from kidneys and purified by TRIzol (Invitrogen, Life Technologies, Paisley, UK). RNA concentration 
and quality was determined using a Nanodrop spectrophotometer and Agilent Bioanalyzer. Across all 
samples the mean 260/280 ratio was 2.06 + /− 0.01, and mean RNA integrity number was 7.9 + /− 0.6. 
cDNA was synthesized using a RT2 First Strand Kit (Qiagen, Manchester, UK). Real-time PCR was then 
performed using a RT2 qPCR primer assay for mouse TLR4 (Qiagen, Manchester, UK). Glyceraldehyde 
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3-phosphate dehydrogenase (GAPDH) was used as the reference gene, and was also quantified using a 
RT2 qPCR primer assay (Qiagen, Manchester UK).
Power calculation. For animal experiments in the renal IRI model, power calculations were performed 
and the number of mice was kept to a minimum required to answer the research question. Creatinine 
was selected as the primary outcome measure since it is objectively measured and less affected by hydra-
tion status than blood urea nitrogen. Although creatinine levels are affected by muscle mass and thus 
differ according to mouse gender and age, all experiments were performed on male mice of the same age. 
Previous data was used to the estimate effect size for the potential reduction in serum creatinine. Based 
on the reduction in creatinine in animals treated with Hsp90 inhibitors that underwent contralateral 
nephrectomy and 30 minutes renal IRI, an effect size of 1.70 was calculated4. With α set at 0.05 and β 
set at 0.1 this translated to a required sample size of 9 animals per treatment group13.
In vitro experiments. Cell culture. Cell lines included human embryonic kidney cells (HEK293) 
(European Collection of Cell Cultures, Porton Down, UK), stably transfected HEK293 expressing TLR4 
(HEK293-TLR4) and stably co-transfected HEK293 expressing both TLR4 and a secreted alkaline phos-
phatase (SEAP) reporter under the transcriptional control of NF-κ B (HEK293-TLR4-NF-κ B) (Imgenex, 
San Diego, USA). Cells were maintained in Dulbecco’s modified eagle’s medium (Gibco, Paisley, UK) sup-
plemented with 10% foetal bovine serum, penicillin (50 U/ml), streptomycin (50 μ g/ml) and non-essential 
amino acids (5%). The selection agent for HEK293-TLR4 cells was 10 μ g/ml blasticidin (Invivogen, San 
Diego, CA) and for HEK293-TLR4-NF-κ B cells were 10 μ g/ml blasticidin, 2 μ g/ml puromycin, 200 μ g/
ml zeocin and 500 μ g/ml G418/geneticin (Invitrogen, Carlsbad, CA).
Drugs and reagents. 17-DMAG was purchased from InvivoGen (San Diego, CA). For in vitro exper-
iments, stock solutions were formed for 17-DMAG and AT13387 in Dimethyl sulfoxide (DMSO) 
(Sigma-Aldridge, Dorset, UK) and further diluted prior to use. DMSO vehicle treated cells served as the 
control. Pre-treatment with Hsp90 inhibitors was performed in a time window 6 or 12 h prior to ligand 
stimulation.
Reagents. TLR4 grade endotoxin-free hyaluronan was purchased from Enzo Life Sciences (Exeter, UK) 
and polymyxin B from SERVA (Heidelberg, Germany).
Transfection. Transient NF-κ B transfections were performed using Fugene HP (Roche, Lewes, East 
Sussex, UK) in the experiment assessing NF-κ B activation in HEK293 cells and HEK293-TLR4 cells, 
as these cells did not have a stably transfected NF-κ B reporter. Transfection efficiency of the NF-κ B 
reporter construct (GL4.32 [luc2P/NF-κ B-RE/Hygro]) was controlled by co-transfecting with a control 
vector (pGL4.73 control vector [hRluc/SV40]) (Promega, Southampton, UK).
Western blot. Western blotting was performed as previously described4. Briefly, whole cells extracts were 
produced and protein concentration determined (BioRad, Hemel Hempstead, UK). Proteins were sepa-
rated by SDS-PAGE (10% Tris/HCl gels) and transferred to nitrocellulose (BioRad, Hemel Hempstead, 
UK). Nitrocellulose membranes were soaked in blocking buffer then primary antibody. Primary antibod-
ies were from the IKK isoform antibody kit (Cell Signaling Technology, Boston, MA). After washing, the 
membranes were exposed to a horseradish peroxidase-conjugated secondary antibody. Enhanced chemi-
luminescence reagent (Amersham, Chalfont St Giles, UK) was applied followed by development with 
autoradiography. Equality of loading was confirmed by probing for β -actin (BD Biosciences, San Diego, 
CA). Autoradiography films were uploaded to a Gel Doc (Bio-Rad, Hemel, UK) using Quantity One 
software before being cropped. The original autoradiography is available in the Supplementary Material.
Flow cytometry. Cells were trypsinised, collected and incubated at room temperature with 2% rabbit 
serum. Further incubation was then performed with either PBS/0.5% Bovine Serum Albumin (BSA)/0.1% 
azide (unstained control), mouse IgG1 isotype control antibody (Serotec, Oxford, UK) or purified mouse 
anti-human TLR4 antibody (BD Pharmingen, San Diego, CA) for test samples (0.5 mg/ml at 1:50 dilu-
tion or 0.5 μ g per test sample). Cells were washed then incubated with either PBS/0.5% BSA/0.1% azide 
for unstained controls or fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Silenus 
Laboratories, Victoria, Australia) for IgG1 control samples and TLR4-test samples. Cells were washed 
again and results acquired on a BD Accuri C6 flow cytometer (BD Biosciences, San Jose, USA).
Luciferase assay. Luciferase assays were used to investigate NF-κ B activity following transient NF-κ B 
transfections in HEK293 and HEK293-TLR4 cells. At 24 h after transfection and following experimen-
tation, cells were processed for luciferase activity using the Dual-Glo luciferase assay system and Turner 
Biosystems Modulus Microplate analyser (Promega, Southampton, UK). Firefly luciferase luminescence 
activity was normalised to that of the co-expressed renilla luciferase to determine the fold induction and 
indicate NF-κ B activity. Maximal signal intensity was achieved 3 h following ligand stimulation with 
hyaluronan.
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SEAP assay. SEAP assays were used to investigate NF-κ B activity in HEK293-TLR4-NF-κ B cells as 
these cells were stably transfected with a SEAP reporter under the transcriptional control of NF-κ B. 
SEAP assays were performed using the SEAPorter assay kit (Imgenex, San Diego, USA). The concentra-
tion of SEAP secreted into cell culture supernatant was calculated from a SEAP standard curve and was 
used to indicate NF-κ B activation. The assay was performed 24 h after the addition of ligands as per the 
manufacturer’s instructions in order to allow adequate time for SEAP to be secreted from cells into the 
culture medium.
Statistical analysis. Data are presented as mean and standard error of the mean or in standard box-
plots with individual results jittered. Statistical comparisons for parametric continuous data were made 
using student’s t-test, one-way analysis of variance (ANOVA) and two-way ANOVA without interac-
tion (using the Tukey’s HSD post hoc correction for multiple comparisons). Statistical comparisons for 
Figure 1. (a) Serum creatinine following AT13387 or vehicle pre-treatment and 24 h following renal IRI 
in FVB/n mice (upper left panel). FVB/n mice were pre-treated with AT13387 or 2Hβ C vehicle (n = 9 
per group). 24 h later, mice were anaesthetised and underwent right nephrectomy and 20 min of left renal 
pedicle clamping. Following 24 h of recovery, blood was obtained by intra-cardiac puncture and serum 
creatinine was determined. Results are presented in a standard boxplot with individual results jittered. 
*p < 0.05 vs. 2Hβ C vehicle, t-test. (b) Tubular necrosis score following AT13387 or vehicle pre-treatment 
and 24 h following renal IRI in FVB/n mice (upper right panel). The left kidney was harvested and placed 
in methacarn. Sections were later prepared and stained with haematoxylin and eosin. A blinded observer 
then determined the tubular necrosis score. Results are presented as mean and standard error of the mean. 
*p < 0.05 vs. 2Hβ C vehicle, Mann-Whitney U test. (c) Morphological kidney injury following pre-treatment 
with vehicle and 24 h following renal IRI in FVB/n mice (lower left panel). A representative section of 
kidney cortex at x 200 magnification is shown. (d) Morphological kidney injury following pre-treatment 
with AT13387 and 24 h following renal IRI in FVB/n mice (lower right panel). A representative section of 
kidney cortex at x 200 magnification is shown.
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non-parametric data were made using the Mann-Whitney U test. All comparisons were performed in R 
v3.0.1 (R Foundation for Statistical Computing).
Results
AT13387 reduces renal IRI and inflammatory signalling in the kidney. AT13387 pre-treatment 
reduces functional and morphological kidney injury from renal IRI. On serum analysis, in comparison 
to vehicle, AT13387 pre-treatment in FVB/n mice significantly reduced creatinine 24 h following renal 
IRI (AT13387 vs. 2Hβ C vehicle, p < 0.05, t-test) (Fig.  1a). AT13387 pre-treatment in FVB/n mice also 
reduced tubular necrosis score (AT13387 vs. 2Hβ C vehicle, p < 0.05, Mann-Whitney U test) (Fig. 1b) on 
histological assessment 24 h following renal IRI (Fig. 1c,d).
AT13387 pre-treatment reduces the expression of TLR4 and inflammatory chemokines in the kidney following 
renal IRI. On PCR analysis, in comparison to vehicle, AT13387 pre-treatment in FVB/n mice significantly 
reduced renal TLR4 expression 24 h following renal IRI (AT13387 vs. Vehicle, p < 0.01, Mann-Whitney 
U test) (Fig.  2). On cytokine array panel, in comparison to vehicle, AT13387 pre-treatment in FVB/n 
mice also reduced renal expression of chemokine (C-X-C motif) ligand 1 (CXCL1) and chemokine 
(C-X-C motif) ligand 2 (CXCL2) 24 h following renal IRI (AT13387 vs. 2Hβ C vehicle, p < 0.05, t-test) 
(Fig. 3). There were no other significant differences in cytokine or chemokine expression.
Development of an in vitro model of sterile inflammatory signalling. Selection of a cell 
line. The absence of TLR4 expression by HEK293 cells was confirmed by flow cytometry (Fig.  4a). 
Successful TLR4 transfection was validated in HEK293-TLR4 cells by flow cytometry (Fig. 4b).
Selection of a TR4-specific and sterile inflammatory ligand. TLR4 was selectively expressed using 
TLR4-transfected cells (HEK293-TLR4). After ligand stimulation NF-κ B activity was assessed by lucif-
erase assay in comparison to TLR4-null cells (HEK293). Following hyaluronan stimulation there was 
increased NF-κ B activity in HEK293-TLR4 cells, but an absence of NF-κ B up-regulation in HEK293 cells 
(HEK293-TLR4 vs. HEK293, p < 0.001, t-test) (Fig. 5a). This indicates that hyaluronan is a TLR4-specific 
ligand in HEK293-TLR4 cells. The level of TLR4-mediated NF-κ B activation assessed by SEAP assay 
following hyaluronan stimulation was not altered by the presence of polymyxin B, a drug that clears 
endotoxin contamination (Fig. 5b).
Figure 2. Renal TLR4 expression following AT13387 or vehicle pre-treatment and 24 h following renal 
IRI in FVB/n mice. FVB/n mice were pre-treated with AT13387 or 2Hβ C vehicle (n = 6 per group) and 
underwent renal IRI as per Fig. 1. The left kidney was harvested and stored in RNAlater for 24 h before 
being frozen. RNA was later extracted and converted to cDNA. PCR was then performed to determine TLR4 
expression. TLR4 expression was normalised to GAPDH expression. Results are presented in a standard 
boxplot with individual results jittered. **p < 0.01 vs. 2Hβ C vehicle, Mann-Whitney U test.
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Hsp90 inhibition represses sterile inflammatory signalling. Hsp90 inhibition abrogates 
TLR4-mediated NF-κB inflammatory activation. In HEK293-TLR4-NF-κ B cells, pre-treatment with 
AT13387 and 17-DMAG significantly reduced hyaluronan-mediated NF-κ B activity assessed by SEAP 
assay (AT13387 1000 nM vs. DMSO vehicle, p < 0.001, 17-DMAG 1000 nM vs. DMSO vehicle, p < 0.001, 
ANOVA). In fact, pre-treatment with AT13387 reduced NF-κ B activity assessed by SEAP assay follow-
ing hyaluronan stimulation to a level equivalent of cells in basal conditions in normal culture medium. 
In addition, AT13387 was significantly more effective at reducing hyaluronan-mediated NF-κ B activity 
assessed by SEAP assay than 17-DMAG (AT13387 1000 nM vs. 17-DMAG 1000 nM, p < 0.01, ANOVA) 
(Fig. 6).
Figure 3. Renal cytokine expression following AT13387 or vehicle pre-treatment and 24 h following 
renal IRI in FVB/n mice. FVB/n mice were pre-treated with AT13387 or 2Hβ C vehicle (n = 4 per group) 
and underwent renal IRI as per Fig. 1. Following 24 h of recovery, the left kidney was harvested and snap 
frozen. Protein lysates were later prepared and an array panel was used to determine cytokine expression. 
The grid describes the cytokines assessed (right panel). A representative array is shown (upper left panel). 
Mean gray values were quantified using Image J and were used to reflect CXCL1 and CXCL2 expression. 
Results are presented in a standard boxplot with individual results jittered (lower left panel). *p < 0.05 vs. 
2Hβ C vehicle, t-test.
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Pre-treatment with AT13387 and 17-DMAG leads to breakdown of the IKK complex. Hsp90 inhibition, 
using pre-treatment with AT13387 and 17-DMAG led to breakdown of the IKK complex on Western blot 
following hyaluronan stimulation in HEK293-TLR4-NF-κ B cells (Fig. 7 and original autoradiography in 
Supplementary Fig. 1).
Discussion
In this study, AT13387 was tested in an established renal IRI model to assess efficacy of this agent 
in reducing renal IRI10. The experiments performed confirmed that AT13387 pre-treatment leads to 
both significant functional and morphological protection from renal IRI. This novel finding highlights 
AT13387 as a potentially exciting new therapy for reducing renal IRI.
Renal IRI predictably occurs in a range of clinical settings including surgery and vascular interven-
tions. It can lead to an acute ischemic kidney injury, potentially life-threatening renal failure, as well as 
remote organ injury and multi-organ failure. Preventative treatment with AT13387 could be adminis-
tered prior to anticipated ischemic insults, in individuals at high-risk of acute ischemic kidney injury 
(e.g. patients with pre-existing kidney disease, diabetes, or previous toxic drug and radiological contrast 
exposure).
Drugs designed to reduce renal IRI have an absolute requirement for low toxicity. Therefore, one of 
the main challenges going forward is to develop low toxicity drugs that can be safely utilised in humans. 
AT13387 is a novel small molecule Hsp90 inhibitor with a low toxicity profile in phase II human studies 
in oncology and therefore better translational potential than 17-DMAG in this context8. Furthermore, 
since there is patient safety data already available for AT13387, it may be possible to more rapidly trans-
late this therapy into a clinical trial. However, prior to this an increased understanding of the mecha-
nisms of protection offered by Hsp90 inhibition is required.
CXCL1 and CXCL2 are NF-κ B target genes, and the expression of these pro-inflammatory chemok-
ines is NF-κ B dependent14,15. It has previously been identified that following renal IRI, there is increased 
expression of CXCL1 and CXCL2. Treatment with neutralizing antibodies to both CXCL1 and CXCL2 
significantly improves kidney function within 48 hours of renal IRI16. The expression of CXCL1 and 
CXCL2 in the kidney was reduced following renal IRI in mice pre-treated with AT13387. There was also 
a significant reduction in renal TLR4 expression. This suggests an anti-inflammatory effect of AT13387. 
However, at just 24 hours following renal IRI, it is likely that protective effect of AT13387 may have 
Figure 4. (a) TLR4 expression by HEK293 cells on flow cytometry (upper panel). Cells were trypsinised 
and collected at 50,000 cells per sample. After processing samples, results were acquired on a BD Accuri C6 
flow cytometer. Cells were gated on the basis of forward (FSC-A) and side scatter (SSC-A). TLR4 expression 
(FLA-1) in HEK293 cells is represented by the red histograms, IgG-FITC negative control sample by the 
pink histograms, PBS-FITC negative control sample by the light blue histograms and PBS-PBS negative 
control sample by the dark blue histograms. (b) TLR4 expression by HEK293-TLR4 cells on flow cytometry 
(lower panel). Cells were analysed and results are reported as per Fig.4a.
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involved programmed cell death rather than inflammation17. Therefore further mechanistic work was 
undertaken, and a carefully designed in vitro model was developed to simulate the sterile inflammatory 
environment of renal IRI.
HEK293 cells were selected specifically for these experiments since they transfect efficiently and have 
previously been reported to lack TLR4 expression18,19. This is in contrast to human renal tubular epithe-
lial cells, which express basal levels of TLR420.
HEK293 and HEK293-TLR4 cells were therefore considered ideal for identifying a suitable 
TLR4-specific ligand to explore in vitro the hypothesis that Hsp90 inhibition leads to repression of 
TLR4-mediated NF-κ B inflammatory activation.
Hyaluronan was selected to stimulate the cells, as it is a damage associated molecular pattern mol-
ecule and a proposed endogenous TLR4 ligand that is released in increasing amounts during the ster-
ile insult that comprises renal IRI5. Hyaluronan was characterised as a sterile TLR4-specific ligand in 
HEK293-TLR4 cells, and was therefore used to model sterile TLR4-specific NF-κ B activation in further 
experiments. It was found that Hsp90 inhibition with AT13387 and 17-DMAG resulted in breakdown of 
IKKα , IKKβ and NEMO, which are the three subunits of the IKK complex21. This reduced highly specific 
TLR4-mediated NF-κ B inflammatory activation by hyaluronan to the level of untreated cells left in basal 
conditions in normal culture medium.
Hsp90 inhibition has previously been used to experimentally treat TLR4-mediated autoimmune dis-
eases22,23 and reduce tumour necrosis factor-alpha-mediated NF-κ B activation24–28. However, this is the 
Figure 5. (a) Luciferase assay to determine NF-κ B activity following NF-κ B transfection and hyaluronan 
stimulation in HEK293 and HEK293-TLR4 cells (left panel). HEK293 and HEK293-TLR4 cells were divided 
at a cell density of 100,000 cells in 1 ml of growth medium per well of a 12-well plate. After 24 h, cells were 
transfected with 0.5 μ g pGL4.32 [luc2P/NF-κ B-RE/Hygro] plasmid DNA (experimental vector) using a ratio 
of DNA to Fugene HP of 3:1. A constitutively active control vector (pGL4.73 [hRluc/SV40]) was added at 
a ratio of experimental to control vector of 100:1. 24 h later, cells were treated with hyaluronan at a dose 
of 25 μ g/ml. After 3 h incubation a luciferase assay was performed to determine firefly activity and renilla 
activity. Fold induction was calculated from the ratio of firefly to renilla and used to reflect NF-κ B activity. 
Results are presented as 3 independent experiments in a standard boxplot with individual results jittered. 
The mean fold induction in HEK293 cells was 1.07 + /− 0.09 (standard error of the mean), i.e. there was no 
increase in NF-κ B activity following hyaluronan stimulation. ***p < 0.001 vs. HEK293 & hyaluronan, t-test. 
(b) SEAP assay to determine NF-κ B activity following hyaluronan stimulation with and without the presence 
of polymyxin B in HEK293-TLR4-NF-κ B cells (right panel). HEK293-TLR4-NF-κ B cells were divided at a 
cell density of 10,000 cells in 100 μ l of growth medium per well of a 96-well plate. 24 h later, the medium 
was changed to medium containing 25 μ g/ml of hyaluronan either with or without 50 μ g/ml of polymyxin B. 
After 24 h incubation a SEAP assay was performed to determine NF-κ B activity. Results are presented from 
4 independent experiments in a standard boxplot with individual results jittered. Outlier data are highlighted 
by a dot with a diamond in the midline.
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Figure 6. NF-κB activity determined by SEAP assay following pre-treatment with AT13387 or 17-
DMAG and hyaluronan stimulation in HEK293-TLR4-NF-κB cells. Cells were divided as per Fig. 5b. 24 h 
later, cells were pre-treated with AT13387, 17-DMAG, DMSO vehicle or medium control for 6 h. With the 
exception of cells left in basal conditions, hyaluronan was added at a dose of 25 μ g/ml for 24 h and a SEAP 
assay was performed to determine NF-κ B activity. Results are presented from 3–4 independent experiments 
in a standard boxplot with individual results jittered. **p < 0.01 vs. 17-DMAG and ***p < 0.001 vs. DMSO 
vehicle, ANOVA.
Figure 7. IKKα, IKKβ and NEMO levels on Western blotting following AT13387 or 17-DMAG pre-
treatment and hyaluronan stimulation in HEK293-TLR4-NF-κB cells. HEK293-TLR4-NF-κ B cells were 
divided at a cell density of 500,000 cells in 2 ml of growth medium per well of a 6-well plate. 24 h later, 
cells were then pre-treated with AT13387, 17-DMAG, DMSO vehicle or medium control for 12 h. With 
the exception of cells pre-treated with medium control, hyaluronan was added for 4 h. Whole-cell lysates 
were then prepared and analysed by Western blotting using antibodies to IKKα , IKKβ and NEMO, with 
β -actin being indicated as a loading control. Three different β -actin levels are presented because three 
separate Western blots were performed on the same samples to avoid antibody interactions. Cropped 
blots are displayed from each Western blot performed and show protein expression levels of IKKα , IKKβ 
and NEMO in the same samples. The gels were run under the same experimental conditions and original 
autoradiography is included in Supplementary Fig. 1.
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first study to identify that TLR4 signalling to NF-κ B can be targeted by Hsp90 inhibitors. This finding 
therefore increases our current understanding of the potential role of Hsp90 in renal IRI, as well as 
inflammatory processes more generally.
In experimental renal IRI, transgenic mice that are missing TLR45,29–31 or that have been treated 
with TLR4-blocking agents demonstrate a markedly protected phenotype32. Furthermore, de-activation 
of NF-κ B with small interfering RNAs or decoy oligodeoxynucleotides targeting either IKKβ or NF-κ B 
transcription factors, protects the kidney from IRI33–35.
The potential of Hsp90 inhibitors to interrupt TLR4-mediated NF-κ B signalling is thus highly attractive 
from a translational perspective since it offers a pharmacological strategy to temporarily dampen NF-κ B 
inflammatory activity. This is in contrast to ablative strategies targeting IKK that reduce NF-κ B-mediated 
inflammation but also prevent subsequent NF-κ B-mediated protection from apoptosis36.
Although numerous pathways can lead to NF-κ B activation, IKK is a common point of convergence 
and activation of NF-κ B occurs nearly universally via IKK-mediated degradation of Iκ B6. Indeed, it has 
previously been shown in HeLa cells that Hsp90 inhibition can prevent the formation of a proposed 
hetero-complex involving IKK and Cdc37/Hsp90, reducing the size of the complex and preventing acti-
vation of NF-κ B26. It has also been observed in alveolar epithelial cells that treatment with Hsp90 inhi-
bition induces dissociation of Hsp90 from the IKK complex, rendering the complex detergent insoluble 
and the NF-κ B system impassive to cytokine stimulation37.
It therefore seems likely that Hsp90 inhibitors repress TLR4-mediated NF-κ B activity primarily 
through IKK. The breakdown of all the major subunits of IKK by AT13387 and 17-DMAG following 
hyaluronan stimulation in this study would support this hypothesis. Although AT13387 was significantly 
more effective at reducing hyaluronan-mediated NF-κ B activity, it does not appear to act through differ-
ent mechanisms from 17-DMAG, However, as it is a smaller molecule Hsp90 inhibitor it may be more 
efficacious in this respect.
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